Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

574 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Miyamoto Y, Tsuji A, Tanioka H, Maekawa S, Kawanaka H, Kitazono M, Oki E, Emi Y, Murakami H, Ogata Y, Saeki H, Shimokawa M, Natsugoe S, Akagi Y, Baba H, Maehara Y. Miyamoto Y, et al. Among authors: natsugoe s. Int J Clin Oncol. 2018 Apr;23(2):402. doi: 10.1007/s10147-017-1212-0. Int J Clin Oncol. 2018. PMID: 29138948
A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Nakajo A, Hokita S, Ishigami S, Miyazono F, Etoh T, Hamanoue M, Maenohara S, Iwashita T, Komatsu H, Satoh K, Aridome K, Morita S, Natsugoe S, Takiuchi H, Nakano S, Maehara Y, Sakamoto J, Aikou T; Kyushu Taxol TS-1 Study Group. Nakajo A, et al. Among authors: natsugoe s. Cancer Chemother Pharmacol. 2008 Nov;62(6):1103-9. doi: 10.1007/s00280-008-0693-y. Epub 2008 Mar 4. Cancer Chemother Pharmacol. 2008. PMID: 18317763 Clinical Trial.
HLA-class I expression in gastric cancer.
Ishigami S, Natsugoe S, Nakajo A, Arigami T, Kitazono M, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K, Aikou T. Ishigami S, et al. Among authors: natsugoe s. J Surg Oncol. 2008 Jun 1;97(7):605-8. doi: 10.1002/jso.21029. J Surg Oncol. 2008. PMID: 18459158
Prognostic value of CD208-positive cell infiltration in gastric cancer.
Ishigami S, Ueno S, Matsumoto M, Okumura H, Arigami T, Uchikado Y, Setoyama T, Arima H, Sasaki K, Kitazono M, Shinchi H, Kijima Y, Natsugoe S. Ishigami S, et al. Among authors: natsugoe s. Cancer Immunol Immunother. 2010 Mar;59(3):389-95. doi: 10.1007/s00262-009-0758-8. Epub 2009 Sep 16. Cancer Immunol Immunother. 2010. PMID: 19760221 Free PMC article.
Prognostic impact of CD168 expression in gastric cancer.
Ishigami S, Ueno S, Nishizono Y, Matsumoto M, Kurahara H, Arigami T, Uchikado Y, Setoyama T, Arima H, Yoshiaki K, Kijima Y, Kitazono M, Natsugoe S. Ishigami S, et al. Among authors: natsugoe s. BMC Cancer. 2011 Mar 24;11:106. doi: 10.1186/1471-2407-11-106. BMC Cancer. 2011. PMID: 21435222 Free PMC article.
Mesothelin expression correlates with prolonged patient survival in gastric cancer.
Baba K, Ishigami S, Arigami T, Uenosono Y, Okumura H, Matsumoto M, Kurahara H, Uchikado Y, Kita Y, Kijima Y, Kitazono M, Shinchi H, Ueno S, Natsugoe S. Baba K, et al. Among authors: natsugoe s. J Surg Oncol. 2012 Feb;105(2):195-9. doi: 10.1002/jso.22024. Epub 2011 Jul 20. J Surg Oncol. 2012. PMID: 21780126
Clinicopathological significance of BMP7 expression in esophageal squamous cell carcinoma.
Megumi K, Ishigami S, Uchikado Y, Kita Y, Okumura H, Matsumoto M, Uenosono Y, Arigami T, Kijima Y, Kitazono M, Shinchi H, Ueno S, Natsugoe S. Megumi K, et al. Among authors: natsugoe s. Ann Surg Oncol. 2012 Jun;19(6):2066-71. doi: 10.1245/s10434-011-2024-5. Epub 2011 Sep 13. Ann Surg Oncol. 2012. PMID: 21913019 Free PMC article.
574 results